NVO
Novo Nordisk A/S
NVO has the edge over OGN overall, supported by stronger valuation and stronger fundamentals.
OGN
Organon & Co.
OGN trails on the overall score without a compensating advantage in the available component scores.
NVO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Stable | |
| Healthy |
NVO's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
OGN Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Stable | |
| Weak |
OGN's revenue, profitability and cash flow are currently stable, but its balance sheet is weak.
NVO PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 10x | $40.65 | — |
| Cheap | 14x | $53.56 | +32% |
| Fair | 27x | $103 | +154% |
| Expensive | 39x | $152 | +273% |
Historical ranges are pointers, not guarantees.
NVO has the edge over OGN in the historical PE scenario, which offers more potential upside but is not a forecast.
OGN PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 3.7x | $2.88 | -79% |
| Forward | 4x | $13.90 | — |
| Fair | 5.6x | $4.34 | -69% |
| Expensive | 7.6x | $5.86 | -58% |
| Current | 18x | $13.90 | — |
Historical ranges are pointers, not guarantees.
OGN's PE is in its expensive range at 18x, but its recent earnings include one-off gains. On analysts' estimates for next year's earnings, today's price would be 4.0x, in its cheap range.
NVO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Growth | |
| Weakening | |
| Limited | |
| Low |
Analysts expect NVO's revenue to grow, but its profitability to weaken. However, they disagree widely on these estimates.
OGN Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Stable | |
| Stable | |
| Improving | |
| Limited | |
| High |
Analysts expect OGN's profitability to improve, with its earnings and revenue holding steady.
NVO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $3.89 | +4.9% |
| Q1 2026 | $4.07 | +17% |
| Q4 2025 | $3.42 | +1.8% |
| Q3 2025 | $3.47 | +10% |
| Q2 2025 | $3.71 | +24% |
| Q1 2025 | $3.49 | +18% |
| Q4 2024 | $3.36 | +21% |
| Q3 2024 | $3.15 | +27% |
NVO has the edge over OGN on earnings, with more consistent year-over-year improvement.
OGN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $3.49 | +353% |
| Q3 2026 | $0.77 | -60% |
| Q2 2026 | $0.78 | -71% |
| Q1 2026 | $0.94 | -67% |
| Q4 2025 | $0.72 | -78% |
| Q3 2025 | $1.92 | -62% |
| Q2 2025 | $2.69 | -31% |
| Q1 2025 | $2.88 | -29% |
| Q4 2024 | $3.33 | -17% |
OGN's earnings per share have fallen from their peak: $0.77 over the past year, against $8.53 in late 2020. Its recent earnings include one-off gains.
NVO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $11.7B | +2.1% |
| Q1 2026 | $14.4B | +24% |
| Q4 2025 | $11.8B | -7.6% |
| Q3 2025 | $11.1B | +5.1% |
| Q2 2025 | $11.4B | +13% |
| Q1 2025 | $11.6B | +19% |
| Q4 2024 | $12.7B | +30% |
| Q3 2024 | $10.6B | +21% |
NVO has the edge over OGN on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 34% | -9 points |
| Q1 2026 | 62% | +12 points |
| Q4 2025 | 40% | -2.8 points |
| Q3 2025 | 32% | -16 points |
| Q2 2025 | 44% | +5.4 points |
| Q1 2025 | 50% | +1 points |
| Q4 2024 | 43% | +2.2 points |
| Q3 2024 | 47% | +1.6 points |
NVO has the edge over OGN on profitability, with a higher operating margin.
OGN Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $1.6B | -1.7% |
| Q2 2026 | $1.6B | -2.3% |
| Q1 2026 | $1.5B | -3.5% |
| Q4 2025 | $1.5B | -5.3% |
| Q3 2025 | $1.6B | +1.3% |
| Q2 2025 | $1.6B | -0.8% |
| Q1 2025 | $1.5B | -6.7% |
| Q4 2024 | $1.6B | -0.4% |
OGN's revenue has held roughly level: $1.6B last quarter, down 1.7% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 16% | +1 points |
| Q2 2026 | 12% | -2.6 points |
| Q1 2026 | 15% | +7.9 points |
| Q4 2025 | -9.8% | -18 points |
| Q3 2025 | 15% | +2.1 points |
| Q2 2025 | 14% | -0.3 points |
| Q1 2025 | 6.7% | -7.9 points |
| Q4 2024 | 8.1% | +1.6 points |
OGN's operating margin was 16% last quarter, up 1 points from the same quarter a year ago.
NVO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $6.3B | +73% |
| Q1 2026 | $1.8B | +20% |
| Q4 2025 | -$5.4B | -$4.7B |
| Q3 2025 | $4.6B | -2.1% |
| Q2 2025 | $3.6B | -34% |
| Q1 2025 | $1.5B | +89% |
| Q4 2024 | -$632.6M | +$390.5M |
| Q3 2024 | $4.7B | +3.3% |
NVO still generates free cash flow, though less than at its 2026 peak: $7.3B over the past year.
OGN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $326M | +50% |
| Q2 2026 | $65M | -64% |
| Q1 2026 | $188M | +337% |
| Q4 2025 | $96M | -71% |
| Q3 2025 | $218M | +120% |
| Q2 2025 | $181M | -40% |
| Q1 2025 | $43M | +43% |
| Q4 2024 | $335M | +5.3% |
OGN still generates free cash flow, though less than at its 2021 peak: $675M over the past year.
NVO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -12.9M shares |
| 1 year | -0.2% | -11M shares |
| 3 years | -1.5% | -66.8M shares |
| 5 years | -3.8% | -177M shares |
| Available history | -6.5% | -311M shares |
NVO has the edge over OGN on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | $520M |
| Q1 2026 | $356.7M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $206.3M |
| Q4 2024 | $1.1B |
| Q3 2024 | $357.4M |
NVO spent $877M buying back its own shares over the past year, down 48% from the year before.
OGN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.7% | +1.9M shares |
| 1 year | +4.5% | +11.7M shares |
| 3 years | +6.3% | +16M shares |
| 5 years | +7.2% | +18.2M shares |
| Available history | +7.6% | +19.3M shares |
OGN has 272M diluted shares, up 4.5% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
NVO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.7x | Very low |
| Q4 2025 | 0.6x | Very low |
| Q3 2025 | 0.4x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.6x | Very low |
| Q3 2024 | -0.0x | Very low |
NVO has the edge over OGN on leverage, with a lower net debt burden relative to earnings.
OGN Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 10.8x | High |
| Q2 2026 | 11.4x | High |
| Q1 2026 | 10.7x | High |
| Q4 2025 | 13.9x | High |
| Q3 2025 | 9.6x | High |
| Q2 2025 | 10.3x | High |
| Q1 2025 | 10.4x | High |
| Q4 2024 | 8.7x | High |
OGN's net debt is about 11 years of its operating earnings (EBITDA), up from 9.6 years a year ago.
NVO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.0 | Neutral |
| Stochastic | 27.0 | Neutral |
NVO's weekly RSI is 43 (neutral) and its Stochastic is 27 (neutral).
OGN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 71.9 | Overbought |
| Stochastic | 99.0 | Overbought |
OGN's weekly RSI is 72 (overbought) and its Stochastic is 99 (overbought).
NVO PE vs Healthcare Sector
| Metric | NVO | Sector median | Relative |
|---|---|---|---|
| PE | 10x | 26x | 60% below |
| PE % | 6 | 29 | 23 pts below |
NVO has the edge over OGN on valuation relative to its sector.
OGN PE vs Healthcare Sector
| Metric | OGN | Sector median | Relative |
|---|---|---|---|
| PE | 18x | 26x | 30% below |
| PE % | 100 | 37 | 63 pts above |
OGN is trading at 18x earnings, a 30% discount to the Healthcare sector's median of 26x, though its recent earnings include one-off gains.
NVO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $39.2 | 3.7% above |
| 20 week MA | $43.9 | 7.4% below |
| 50 week MA | $45.3 | 10% below |
| 100 week MA | $56.3 | 28% below |
| 200 week MA | $80.7 | 50% below |
NVO has bounced recently, but its long-term trend is still down: it's above its 8-week average, but 50% below its 200-week average.
OGN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $13.8 | 0.7% above |
| 20 week MA | $13.7 | 1.5% above |
| 50 week MA | $11.1 | 25% above |
| 100 week MA | $11.2 | 24% above |
| 200 week MA | $15.4 | 9.4% below |
OGN has the edge over NVO on trend strength, trading above more of its moving averages.
NVO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $29.1 | $34.7 | +19% |
| 2021 | $34.7 | $54.2 | +56% |
| 2022 | $54.2 | $67.0 | +24% |
| 2023 | $67.0 | $103.5 | +54% |
| 2024 | $103.5 | $87.4 | -16% |
| 2025 | $87.4 | $52.4 | -40% |
| 2026 YTD | $52.4 | $40.7 | -22% |
NVO has finished higher in four of the last six years, two of them by more than 50%. It's down 22% so far in 2026.
OGN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $33.3 | $30.2 | -9.1% |
| 2022 | $30.2 | $27.9 | -7.6% |
| 2023 | $27.9 | $14.4 | -48% |
| 2024 | $14.4 | $15.1 | +4.4% |
| 2025 | $15.1 | $7.18 | -52% |
| 2026 YTD | $7.18 | $13.9 | +94% |
OGN has the edge over NVO on returns for 2026, with the stronger performance.